SG11201406629VA - (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators - Google Patents
(2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulatorsInfo
- Publication number
- SG11201406629VA SG11201406629VA SG11201406629VA SG11201406629VA SG11201406629VA SG 11201406629V A SG11201406629V A SG 11201406629VA SG 11201406629V A SG11201406629V A SG 11201406629VA SG 11201406629V A SG11201406629V A SG 11201406629VA SG 11201406629V A SG11201406629V A SG 11201406629VA
- Authority
- SG
- Singapore
- Prior art keywords
- ureidoacetamido
- modulators
- alkyl derivatives
- peptide receptor
- formyl peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
- C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624495P | 2012-04-16 | 2012-04-16 | |
| PCT/US2013/036715 WO2013158597A1 (en) | 2012-04-16 | 2013-04-16 | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406629VA true SG11201406629VA (en) | 2014-11-27 |
Family
ID=48183042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406629VA SG11201406629VA (en) | 2012-04-16 | 2013-04-16 | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9670150B2 (en) |
| EP (1) | EP2838887B1 (en) |
| JP (1) | JP2015520130A (en) |
| KR (1) | KR20140145203A (en) |
| CN (1) | CN104302630A (en) |
| AU (1) | AU2013249474A1 (en) |
| CA (1) | CA2870356A1 (en) |
| ES (1) | ES2711363T3 (en) |
| NZ (1) | NZ700733A (en) |
| SG (1) | SG11201406629VA (en) |
| WO (1) | WO2013158597A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104114164B (en) | 2011-10-26 | 2016-11-16 | 阿勒根公司 | The substituted amino acid whose amide derivatives of N-urea as formyl peptide receptor sample-1 (FPRL-1) receptor modulators |
| CN110279684B (en) | 2013-03-06 | 2023-02-28 | 阿勒根公司 | Use of formyl peptide receptor 2 agonists for the treatment of ocular inflammatory diseases |
| CA3114477A1 (en) * | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
| EP3071548B1 (en) * | 2013-11-21 | 2017-11-08 | Allergan, Inc. | Phenylcarbamate derivatives as formyl peptide receptor modulators |
| NO3075726T3 (en) | 2013-11-28 | 2018-04-07 | ||
| WO2015116574A1 (en) * | 2014-01-29 | 2015-08-06 | Allergan, Inc. | Urea hydantoin derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| BR112016027133A8 (en) | 2014-05-21 | 2021-06-29 | Allergan Inc | imidazole derivatives as formyl peptide receptor modulators, pharmaceutical composition and use |
| TW201718473A (en) * | 2015-08-05 | 2017-06-01 | 歐樂根公司 | Phenyl urea analogs as formyl peptide receptor 1 (FPR1) selective agonists |
| CN109641857A (en) * | 2016-04-12 | 2019-04-16 | 阿勒根公司 | Phenyl Urea Derivatives as N- formyl peptide receptor regulator |
| ES2869129T3 (en) * | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Formylated peptide receptor 2 piperidinone agonists |
| CN110996950B (en) * | 2017-06-09 | 2023-04-04 | 百时美施贵宝公司 | Piperidinone formyl peptide 2 receptor agonists and formyl peptide 1 receptor agonists |
| CN109593067B (en) * | 2017-09-30 | 2021-11-26 | 暨南大学 | Tetrazole molecular probe compound or composition and application thereof |
| ES2904483T3 (en) | 2018-03-05 | 2022-04-05 | Bristol Myers Squibb Co | Formyl peptide receptor 2 phenylpyrrolidinone agonists |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2608336A1 (en) * | 1975-03-11 | 1976-09-30 | Sandoz Ag | NEW ORGANIC COMPOUNDS, THEIR PRODUCTION AND USE |
| US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
| JPS57102896A (en) * | 1980-12-18 | 1982-06-26 | Grelan Pharmaceut Co Ltd | N-substituted aminophosphonic acid |
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| CA2071621C (en) | 1991-06-19 | 1996-08-06 | Ahihiko Hosoda | Aldehyde derivatives |
| JP2697495B2 (en) * | 1991-06-19 | 1998-01-14 | 富士レビオ株式会社 | Aldehyde derivatives |
| US5686419A (en) * | 1994-01-21 | 1997-11-11 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| EP1162194A1 (en) * | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| US7109243B2 (en) * | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CN100506802C (en) | 2004-06-04 | 2009-07-01 | 中国科学院上海药物研究所 | Formyl peptide-like acceptor-1 regulator and its Preparation and use |
| WO2006065755A2 (en) * | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| EP2585054A1 (en) * | 2010-06-24 | 2013-05-01 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| CN110279684B (en) * | 2013-03-06 | 2023-02-28 | 阿勒根公司 | Use of formyl peptide receptor 2 agonists for the treatment of ocular inflammatory diseases |
| CA3114477A1 (en) * | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
-
2013
- 2013-04-16 WO PCT/US2013/036715 patent/WO2013158597A1/en active Application Filing
- 2013-04-16 NZ NZ700733A patent/NZ700733A/en not_active IP Right Cessation
- 2013-04-16 US US13/863,934 patent/US9670150B2/en active Active
- 2013-04-16 CA CA2870356A patent/CA2870356A1/en not_active Abandoned
- 2013-04-16 AU AU2013249474A patent/AU2013249474A1/en not_active Abandoned
- 2013-04-16 KR KR1020147031783A patent/KR20140145203A/en not_active Application Discontinuation
- 2013-04-16 SG SG11201406629VA patent/SG11201406629VA/en unknown
- 2013-04-16 JP JP2015507101A patent/JP2015520130A/en active Pending
- 2013-04-16 CN CN201380025558.9A patent/CN104302630A/en active Pending
- 2013-04-16 EP EP13718477.6A patent/EP2838887B1/en active Active
- 2013-04-16 ES ES13718477T patent/ES2711363T3/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2711363T3 (en) | 2019-05-03 |
| EP2838887B1 (en) | 2018-11-21 |
| CN104302630A (en) | 2015-01-21 |
| KR20140145203A (en) | 2014-12-22 |
| CA2870356A1 (en) | 2013-10-24 |
| WO2013158597A1 (en) | 2013-10-24 |
| US20130274230A1 (en) | 2013-10-17 |
| EP2838887A1 (en) | 2015-02-25 |
| US9670150B2 (en) | 2017-06-06 |
| JP2015520130A (en) | 2015-07-16 |
| AU2013249474A1 (en) | 2014-11-06 |
| NZ700733A (en) | 2016-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201406629VA (en) | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | |
| IL237212A0 (en) | Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators | |
| IL251897A0 (en) | Liver x receptor modulators | |
| PL2663550T4 (en) | Substituted benzoazepines as toll-like receptor modulators | |
| PL2663555T4 (en) | Substituted benzoazepines as toll-like receptor modulators | |
| IL232112A0 (en) | Novel substituted imidazopyrimidines as gpbar1 receptor modulators | |
| IL227779A0 (en) | Cannabinoid receptor modulators | |
| HK1206333A1 (en) | Liver receptor modulators | |
| ZA201308942B (en) | Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators | |
| IL235557A0 (en) | Gpr17 receptor modulators | |
| HK1211916A1 (en) | Arylalkylamine compounds as calcium sensing receptor modulators | |
| ZA201402068B (en) | Ethynyl derivates as metabotropic glutamate receptor modulators | |
| HUE038700T2 (en) | Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators | |
| EP2922539A4 (en) | Substituted isoquinolines as crth2 receptor modulators |